Session » Antiphospholipid Syndrome - Poster I

Date: Monday, November 14, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

Abstract Number: 1059

Quality of Life in Patients with Antiphospholipid Syndrome Is Related to Disease Burden and Anticoagulant Therapy

Abstract Number: 1060

Antiphospholipid Antibodies and Related Clinical Events Following Infection in Children: A Systematic Review of Case Reports

Abstract Number: 1061

Identifying Clinical and Epidemiological Risk Factors Associated with Thrombosis and Pregnancy Morbidity in a Large Cohort of Chinese APS Patients

Abstract Number: 1062

Non-Conventional Antiphospholipid Antibodies in Patients with Clinical Obstetrical APS: Prevalence and Pregnancies Treatment Efficacy

Abstract Number: 1063

A Systematic Review of Direct Oral Anticoagulant Use in Antiphospholipid Syndrome

Abstract Number: 1064

Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: Direct Oral Anticoagulant Use Among Antiphospholipid Syndrome Patients

Abstract Number: 1065

A Practical Application of Antiphospholipid Antibodies Profiles in the Diagnosis and Managements of Antiphospholipid Syndrome: The Modified Antiphospholipid Score

Abstract Number: 1066

History of Lupus Nephritis Is an Independent Risk Factor for Thrombosis in Systemic Lupus Erythematosus Patients with Antiphospholipid Antibodies

Abstract Number: 1067

History of Thrombocytopenia Is Associated with Lower Prevalence of Thrombotic Events in Systemic Lupus Erythematosus Patients with Antiphospholipid Antibodies

Abstract Number: 1068

Recurrence of Thrombosis Despite Negativization of Antiphospholipid Antibodies in Primary Antiphospholipid Syndrome. a Follow-up to 5 Years

Abstract Number: 1069

The Predictive Value of Acl and Anti-β2GPI in Patients with Acute Deep Vein Thrombosis

Abstract Number: 1070

Performance and External Validation of the Damage Index in Antiphospholipid Syndrome in Primary and Secondary APS Patients

Abstract Number: 1071

Anti-β2GP-I-Domain 3 and Aps/PT-IgG Antibodies Identify Primary APS Patients with Both Thrombotic and Hematological Manifestations

Abstract Number: 1072

Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: Cardiovascular Risk Factors Among Different Groups of Antiphospholipid Antibody-Positive Patients

Abstract Number: 1073

Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking (APS ACTION) Clinical Database and Repository Analysis: The Comparison of Real World and Core Laboratory Antiphospholipid Antibody ELISA Results

Abstract Number: 1074

The Risk of Obstetric Complications and the Effects of Treatment in Women with Low Titer and Medium-High Titer Anti-Phospholipid Antibodies

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.